Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 24,300 shares, an increase of 54.8% from the October 31st total of 15,700 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 49,800 shares, the days-to-cover ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Oculis in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $29.20.

Oculis Price Performance

Shares of NASDAQ:OCS traded down $0.12 during trading on Friday, hitting $16.04. 32,043 shares of the company's stock were exchanged, compared to its average volume of 37,117. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. Oculis has a 52-week low of $9.60 and a 52-week high of $18.00. The business's 50-day simple moving average is $14.88 and its 200 day simple moving average is $12.86. The company has a market cap of $649.62 million, a price-to-earnings ratio of -8.37 and a beta of -0.16.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The business had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.28 million. As a group, equities analysts predict that Oculis will post -2.09 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.